EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Carbapenem-Resistant Acinetobacter baumannii: Virulence Factors, Molecular Epidemiology, and Latest Updates in Treatment Options

Theodoros Karampatakis iD, Katerina Tsergouli, Payam Behzadi iD

Microorganisms · 26.08.2025 · 13 (9) · 1983

DOI: 10.3390/microorganisms13091983 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Microorganisms, online erschienen am 26.08.2025. Verfasst von Theodoros Karampatakis und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Microbiology, University Hospital Kerry, V92 NX94 Tralee, Ireland. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 327 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acinetobacter baumannii is a Gram-negative, non-motile pathogen commonly associated with healthcare settings. It is capable of causing severe infections, particularly in immunocompromised and critically ill individuals, and is linked to poor clinical outcomes. Infections caused by carbapenem-resistant A. baumannii (CRAB) represent a major public health concern due to limited treatment options and high resistance rates. Several virulence determinants contribute to CRAB’s pathogenicity, including capsular exopolysaccharide (CPS), lipopolysaccharide (LPS), lipooligosaccharide (LOS), efflux pumps, outer membrane proteins (OMPs), pili, metal acquisition systems, two-component regulatory systems (TCSs), and secretion systems (SSs). The dominant resistance mechanism in CRAB involves the production of carbapenemases, most notably oxacillinase-23 (OXA-23) and metallo-β-lactamases (MBLs) such as Verona integron-encoded MBL (VIM) and New Delhi MBL (NDM). Accurate identification of these resistance mechanisms is crucial for guiding effective antimicrobial therapy. Potential treatment options include older agents like polymyxins, ampicillin–sulbactam, high-dose carbapenems, tigecycline, and minocycline, along with newer antimicrobials such as eravacycline, cefiderocol, and aztreonam–avibactam. This review aims to explore the virulence mechanisms and molecular pathogenesis of CRAB, while also presenting recent developments in its epidemiology and available antimicrobial therapies.

Schlagwörter

Stichwörter der Autor:innen

antimicrobial agentsantimicrobial treatmentcarbapenem-resistant Acinetobacter baumanniimolecular epidemiologyvirulence factors

Autor:innen und Institutionen

  • Department of Clinical Microbiology, University Hospital Kerry, V92 NX94 Tralee, Ireland.
  • Department of Microbiology, ShQ.C., Islamic Azad University, Shahr-e Qods 37541-374, Iran.

ORCID-Profile: Theodoros Karampatakis, Payam Behzadi

Zitieren

APA

Karampatakis, T., Tsergouli, K., & Behzadi, P. (2025). Carbapenem-Resistant Acinetobacter baumannii: Virulence Factors, Molecular Epidemiology, and Latest Updates in Treatment Options. Microorganisms, 13(9), 1983. https://doi.org/10.3390/microorganisms13091983

Vancouver

Karampatakis T, Tsergouli K, Behzadi P. Carbapenem-Resistant Acinetobacter baumannii: Virulence Factors, Molecular Epidemiology, and Latest Updates in Treatment Options. Microorganisms. 2025;13(9):1983. doi:10.3390/microorganisms13091983

BibTeX
@article{Karampatakis2025,
  author = {Karampatakis, Theodoros and Tsergouli, Katerina and Behzadi, Payam},
  title = {Carbapenem-Resistant Acinetobacter baumannii: Virulence Factors, Molecular Epidemiology, and Latest Updates in Treatment Options},
  journal = {Microorganisms},
  year = {2025},
  volume = {13},
  number = {9},
  pages = {1983},
  doi = {10.3390/microorganisms13091983}
}
Kostenlos starten →